First UK Customers for IORT Treatment

RNS Number : 8438C

Advanced Oncotherapy PLC

22 April 2013

 



22 April 2013

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or "the Company")

First UK Customers for IORT Treatment

BMI Healthcare Hospital and Montefiore Hospital (Spire) Adopt New Patient Focused Breast Cancer Radiation Treatment

Advanced Oncotherapy (AIM: AVO) announces that consultants at two hospitals in the UK - BMI Chelsfield Park Hospital and the Montefiore Spire Hospital in Hove - have successfully utilised a new single dose form of intraoperative radiation therapy (IORT) for early stage 2 breast cancer patients.  The new therapy is being provided by Oncotherapy Resources Ltd, a subsidiary of Advanced Oncotherapy.

The new technology, Xoft® System for IORT, provides patients with multiple benefits including reduced radiation exposure to healthy tissue and organs. IORT with Xoft® also eliminates the need for external beam radiation treatments in certain selected patient groups which requires patients to travel to their hospital for 15 - 25 days consecutively for continued treatment. Patients can return to their normal life and daily routines more quickly with the Xoft® electronic brachytherapy system because the surgery and radiation are administered at the same time.

In the UK, breast surgeons conduct 20,000 lumpectomy operations annually for breast cancer. Consultant Clinical Oncologist, Dr Richard Simcock, Lead  Clinician for Breast Care at Brighton and Sussex University Hospitals NHS, comments "Radiotherapy is an essential part of the treatment for early breast cancer and reduces recurrences and improves survival. Standard external beam radiation therapy is resource intensive for radiotherapy departments with up to 30% of patients being treated for breast cancer. IORT offers the potential to reduce significant treatment burden and patient inconvenience whilst also freeing up vital external beam radiation machine capacity for other cancer patients."

Oncoplastic and Reconstructive Breast Surgeon, Mr Anil Desai at BMI Chelsfield Park Hospital commented: "The IORT procedure with the Xoft® System not only reduces costs, but also increases the accessibility of radiation treatment to the vast majority patients with early stage breast cancer. Currently in the UK there are only a few centres that offer IORT, but with this new managed mobile service, more hospitals, consultants and patients will be able to access a treatment that can dramatically streamline patient pathways and improve the patient experience."

 

On the launch of the AVO's managed mobile service, Chief Executive, Dr Mike Sinclair added "We have established Advanced Oncotherapy with the objective of providing convenient, cost-effective and clinically superior treatment to patients with cancer. The inauguration of our IORT managed service for patients with early stage breast cancer meets all these objectives. We are proud to be associated with the leading UK clinicians involved in the roll out of this patient focussed treatment."

For further information, please visit www.advancedoncotherapy.comor contact:

Michael Sinclair, Chief Executive	Sandy Jamieson	Jon Levinson	Simon Hudson
Advanced Oncotherapy Group Plc	Libertas Capital Corporate Finance Ltd	Peterhouse Corporate Finance	Tavistock Communications
0203 617 8739	(NOMAD & Joint Broker)	(Joint Broker)	(Financial PR & IR)
	020 7569 9650	020 7469 0930	020 7920 3150

About Advanced Oncotherapy Plc  

1.    Advanced Oncotherapy is a provider of new technology for innovative and patient-focused cancer treatments. These are technologies endorsed internationally by UK and global cancer clinicians and surgeons.

2.    AVO has exclusivity for the Xoft® System in the UK and Ireland and offers a managed mobile service to hospitals thereby providing their patients with radiation treatment closer to home.

3.    The Xoft® System provides a therapeutic dose of radiation directly to the region at risk with minimal radiation exposure to surrounding healthy tissue and without the complex handling, resource logistics and costs associated with using radioactive isotopes.

4.    For more information please visit: http://www.advancedoncotherapy.com/IORTEarlystage.aspx

 

END

 

 

NRADMGZDNMNGFZM